Eight threads — the commercial story, the new approval, the trial readouts coming.
↓ scroll to read
✦ The bottom line
NovoCure's Q1 release is a mid-launch update with multiple binary catalysts ahead. Here's how management framed the quarter.
↓ the brief below
✦ Eight threads from the Q1 2026 earnings release
1
Revenue grew 12%.
$174M total revenue, up 12% YoY — with Europe contributing meaningfully (one-time benefits in Germany +$2.5M, France +$1M) and Greater China's Zai Lab partnership adding $4.8M.
2
Optune Pax launched in the U.S.
Following Feb 2026 FDA approval for locally advanced pancreatic cancer, 83 active patients and 169 prescriptions in Q1 — first launch of a TTFields product in eight years.
3
Optune Lua adoption is accelerating internationally.
Active patients on Optune Lua up 56% YoY — including new Japan reimbursement coverage announced in March 2026.
4
Gross margin expanded to 78%.
Up from 75% a year earlier — software-like for a hardware-delivered therapy, driven by lower transducer array costs.
5
Adjusted EBITDA was nearly breakeven.
-$300K — first quarter ever within shouting distance of breakeven on the company's preferred operating metric.
6
GAAP G&A spiked.
$85.9M of G&A (up 92%) — but driven almost entirely by a $43M one-time non-cash share-based compensation charge triggered by the Optune Pax FDA approval. Underlying G&A grew far less.
7
PANOVA-4 hit its primary endpoint.
Phase 2 pancreatic cancer trial showed 74% disease control rate with TTFields + atezolizumab + chemo vs. 48% control — meaningful signal for first-line metastatic pancreatic cancer.
8
Three major catalysts loom.
Phase 3 TRIDENT glioblastoma data (Q2 2026), FDA PMA decision on TTFields for NSCLC brain metastases (Q4 2026), and KEYNOTE D58 enrollment complete (Q4 2026).